When: Tuesday, October 22, 2024 12:00 pm -1:00 pm EDT
Trial #1: (CCTG) SC.29: A Randomized Phase III Trial Comparing Stereotactic Body Radiotherapy to Conventional Palliative Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Participants With Painful Non-Spine Bone Metastases
Speaker: Dr. Arjun Sahgal, MD, Chief of Radiation Oncology and the Radiation Treatment Program, Sunnybrook Health Sciences Centre; Radiation Oncologist, Sunnybrook Health Sciences Centre; Professor of Radiation Oncology, University of Toronto; Director of the Cancer Ablation Therapy (CAT) program, Senior Scientist, Sunnybrook Research Institute; President of the International Stereotactic Radiosurgery Society (ISRS)
Trial #2: (CCTG) AL.6: A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
Speaker: Dr. Sarit Assouline, MSc, MD, FRCPC, Hematologist, Jewish General Hospital; Associate Professor, Department of Medicine, McGill University; Associate Director, Clinical Research Unit, Segal Cancer Center of the Jewish General Hospital; Co-Chair of Hematology Disease Site Group, Canadian Cancer Trials Group (CCTG)
Tags:
Posted on: